Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Syndrome of pleural and retrosternal "bridging" fibrosis and retroperitoneal fibrosis in patients with asbestos exposure.
BMJ case reports·2025
Same author
A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2020
Same author
Pilot experience of multidisciplinary team discussion dedicated to inherited pulmonary fibrosis.
Orphanet journal of rare diseases·2019
Related Experiment Video
Updated: Jul 5, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
[Idiopathic pulmonary fibrosis].
Vincent Cottin1, Jean-François Cordier
1Service de Pneumologie, Centre de Référence des Maladies Orphelines Pulmonaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Université Lyon I, UMR 754 INRA ENVL IFR128, Lyon, France. vincent.cottin@chu-lyon.fr
Presse Medicale (Paris, France : 1983)
|May 20, 2008
Summary
Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with a poor prognosis. Current treatments offer limited benefit, highlighting the urgent need for effective therapies for this incurable condition.
Area of Science:
- Pulmonology
- Pathology
- Radiology
Context:
- Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease.
- Histopathological hallmarks include usual interstitial pneumonia (UIP) pattern, fibrosis, and honeycomb lung.
- Diagnosis relies on multidisciplinary assessment: clinical, radiological (HRCT), and pathological findings.
Purpose:
- To describe the diagnostic criteria and current management of Idiopathic Pulmonary Fibrosis.
- To highlight the challenges in diagnosing and treating IPF.
- To review the limited efficacy of current treatments and ongoing research.
Summary:
- IPF diagnosis involves clinical evaluation, high-resolution computed tomography (HRCT), and sometimes lung biopsy.
- In 50% of cases, characteristic HRCT patterns enable confident diagnosis without biopsy.
- Median survival is approximately 3 years, with no definitive cure.
Impact:
- Current treatments, including N-acetylcysteine with corticosteroids and azathioprine, may slightly slow functional decline.
- The disease remains largely incurable, emphasizing the critical need for novel therapeutic strategies.
- Ongoing clinical trials aim to develop improved treatments for IPF patients.